Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million

pharmafile | December 20, 2018 | News story | Business Services, Medical Communications, Sales and Marketing CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncology 

German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a deal worth $175 million.

Intrexon will hand over $150 million in stock and a $25 million convertible note. The company will in turn receive a $25 million cash investment. Thus Merck will maintain an investment in the next generation of CAR-T therapies.

The new deal comes three years after Merck forged a $941 million deal with Intrexon in 2015. Merck has characterised the move as an attempt to streamline their R&D processes.

However the firm has failed to make a lasting impression when it comes to CAR-T therapies having been overtaken by Swiss firm Novartis and Gilead subsidiary Kite. Shares in Intrexon were up 8% premarket but down overall.

Louis Goss

Related Content

Exscientia enters AI drug discovery collaboration with Merck KGaA

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content